Home     About SABCS     Press Releases     Media     Event Photos     Past Symposia     Satellite Symposia     Patient Advocates     FAQs     Contact Us

Registration           Hotel           Support & Exhibits     2014 Overview           Program           Travel & Transportation          

Quick Links
Career Development Forum Reg Form
SABCS 2013 Program Book pdf

Schedule at a Glance
Daily Schedule:
Tue. 12/9/2014
Wed. 12/10/2014
Thu. 12/11/2014
Fri. 12/12/2014
Sat. 12/13/2014
Poster Sessions:
Poster Session 1
Poster Session 2
Poster Session 3
Poster Session 4
Poster Session 5
Poster Session 6
Poster Session OT1
Poster Session OT2
Poster Session OT3
Poster Discussions:
Poster Discussion 1
Poster Discussion 2
Poster Discussion 3
Poster Discussion 4
Poster Discussion 5
Poster Discussion 6

Program Schedule   >  Poster Sessions - Poster Session 6

Poster Session 6 
  Tumor Cell and Molecular Biology: Angiogenesis
P6-01-01 Diet-induced obesity increases tumor growth and promotes angiogenesis in a murine model of breast cancer
Vona-Davis L, Coad J, Olfert M. West Virginia University, Morgantown, WV.
P6-01-02 Celecoxib alleviates tamoxifen-instigated angiogenic effects by ROS-dependent VEGF/VEGFR2 autocrine signaling
Mandal M, Prasanth Kumar B. School of Medical Science and Technology, Indian Institute of Technology, Kharagpur, West Bengal, India.
  Tumor Cell and Molecular Biology: Apoptosis and Senescence
P6-02-01 Elucidating the change of TRAIL sensitivity in basal like TNBC cell lines by lapatinib, and further therapeutic implication
Lim B, Dolloff NG, Allen JE, Dicker DT, El-Deiry WS. Penn State Hershey Medical Center, Hershey, PA.
P6-02-02 mRNA expression of death associated protein 3 (DAP3) and human breast cancer: Clinical correlations and in vitro evidence
Wazir U, Ye L, Sanders AJ, Jiang WG, Sharma AK, Mokbel K. St Georges' Healthcare NHS Trust, London, United Kingdom; Cardiff University-Peking University Oncology Joint Institute, Cardiff, United Kingdom; The London Breast Institute, The Princess Grace Hospital, London, United Kingdom.
P6-02-03 TGF-β1-inducible protein BIGH3 (transforming growth factor beta-induced gene human clone 3): A new mechanism inducing breast cancer cell apoptosis
RezaPoor F, Moritz R, Phelix CF, LeBaron RG. University of Texas at San Antonio, San Antonio, TX.
  Tumor Cell and Molecular Biology: Etiology/Carcinogenesis
P6-03-01 Low dose exposure of non-malignant breast epithelial cells to the polyester and PET precursor, terephthalic acid, triggers broad-based dysfunctional changes
Dairkee SH, Luciani-Torres G, Goodson III WH. California Pacific Medical Center Research Institute, San Francisco, CA.
P6-03-02 Withdrawn
  Tumor Cell and Molecular Biology: Novel/Emerging Targets
P6-04-01 Protein pathway activation mapping of LCM tumor epithelium from I-SPY 1 TRIAL surgical specimens reveals activation of receptor tyrosine kinase drug target signaling networks in the non-responding patient cohort
Wulfkuhle JD, Gallagher RI, Wolf D, Yau C, I-SPY Trial 1 Investigators, Liotta LA, van 't Veer L, Esserman L, Petricoin III EF. George Mason University, Manassas, VA; University of California San Francisco, San Francisco, CA.
P6-04-02 Defining clinically relevant molecular subtypes in lobular breast cancer within the RATHER consortium
Linn S, Majewski I, Michaut M, Peeters J, Schouten P, de Koning L, He B, Fan Y, Tarrant F, Oconnor D, Rueda O, Chin S-F, Heijmans J, Snel M, Severson T, Bosma A, Mittempergher L, Bismeijer T, Dubois T, Wessels L, Simon I, Gallagher W, Caldas C, Bernards R. The Netherlands Cancer Institute, Amsterdam, Netherlands; Agendia NV, Amsterdam, Netherlands; Institut Curie, Paris, France; University College Dublin, Dublin, Ireland; OncoMark Limited, Dublin, Ireland; Cambridge Research Institute, Cambridge, United Kingdom.
P6-04-03 ERβ and breast cancer: A potential predictive and prognostic biomarker and novel therapeutic drug target
Hawse JR, Subramaniam M, Reese JM, Wu X, Negron V, Gingery A, Pitel KS, Shah SS, Cunliffe HE, McCullough AE, Pockaj BA, Couch FJ, Reynolds C, Lingle WL, Suman VJ, Spelsberg TC, Goetz MP, Ingle JN. Mayo Clinic, Rochester, MN; Translational Genomics Research Institute, Phoenix, AZ; Mayo Clinic, Scottsdale, AZ.
P6-04-04 Maternal embryonic leucine zipper kinase (MELK) is a novel radiosensitizing and therapeutic target and is independently prognostic in triple-negative breast cancer
Speers C, Liu M, Alluri P, Batra N, Brown P, Pierce L, Feng F. University of Michigan, Ann Arbor, MI; M.D. Anderson Cancer Center, Houston, TX.
P6-04-05 GPR110 overexpression increases tumorigenic potential of HER2+ breast cancer cells
Trivedi MV, Bhat R, Yadav V, Yadav P, Al-rawi A, Christiny P, Nanda S, Giuliano M, Creighton C, Osborne CK, Narkar VA, Schiff R. University of Houston College of Pharmacy, Houston, TX; Lester and Sue Smith Breast Center, Dan L. Duncan Cancer Center, Baylor College of Medicine, Houston, TX; Baylor College of Medicine, Houston, TX; Center for Metabolic and Degenerative Diseases, Institute of Molecular Medicine, University of Texas, Houston, TX.
P6-04-06 Targeting cancer stem cells in triple negative breast cancer by a combination treatment of LBH589 and salinomycin
Kai M, Kanaya N, Warden C, Luu T, Chen S. Beckman Reseach Institute, City of Hope, Duarte, CA; Bioinformatics Core, City of Hope National Medical Center, Duarte, CA; City of Hope Cancer Center, Duarte, CA.
P6-04-07 Transcriptional regulation of MYB by estrogen receptor α in breast cancer can be targeted by CDK9 inhibitors
Mitra P, Ramsey R, Gonda TJ. University of Queensland, Brisbane, QLD, Australia; Peter MacCallum Cancer Centre, Melbourn, VIC, Australia.
P6-04-08 Cytosolic phospholipase A2 (cPLA2) as a therapeutic target in basal-like breast cancer
Moestue SA, Grinde MT, Marangoni E, Sørlie T, Engebråten O, Mælandsmo GM, Johansen B, Bathen TF. Norwegian University of Science and Technology (NTNU), Trondheim, Norway; Institut Curie, Paris, France; Oslo University Hospital Radiumhospitalet, Oslo, Norway; Avexxin AS, Trondheim, Norway.
P6-04-09 Dual PI3K and Wnt pathway inhibition is a synergistic combination against triple negative breast cancer
Solzak JP, Atale R, Hancock BA, Radovich M. Indiana University School of Medicine, Indianapolis, IN.
P6-04-10 Components of cap-independent translation as novel targets in breast cancer
Ward TM, Harrell C, Liu X, Pegram MD. Stanford University School of Medicine, Palo Alto, CA; University of North Carolina-Lineberger Comprehensive Cancer Center, Chapel Hill, NC.
P6-04-11 Use of synthetic isoprenoids to target protein prenylation and Rho GTPases in breast cancer invasion
Chen M, Knifley T, Subramanian T, Spielmann HP, O'Connor KL. University of Kentucky, Lexington, KY.
P6-04-12 CDK inhibition mediates tumor suppressive Smad3 action and decreased metastatic phenotypes in triple negative breast cancer cells
Tarasewicz E, Rivas LR, Hamdan R, Shea L, Jeruss JS. Northwestern University Feinberg School of Medicine, Chicago, IL.
P6-04-13 Preclinical testing using a novel CT20p peptide-nanoparticle combination in breast cancer
Vishnubhotla PS, Boohaker RJ, Lee MW, Nemec KN, Santra S, Khaled AS, Perez M, Khaled AR. Orlando VA Medical Center, Orlando, FL; University of Central Florida, Orlando, FL.
P6-04-14 mRNA expressions of lamin B1 and lamin B receptor: Clinical correlations with human breast cancer
Wazir U, Ahmad MH, Bridger JM, Harvey A, Jiang WG, Sharma AK, Mokbel K. The London Breast Institute, The Princess Grace Hospital, London, United Kingdom; Centre for Cell & Chromosome Biology, 4Brunel Institute for Cancer Genetics and Pharmacogenomics, School of Health Sciences and Social Care, Uxbridge, London, United Kingdom; Cardiff University School of Medicine, Cardiff University, Cardiff, United Kingdom; St. George's Hospital and Medical School, University of London, London, United Kingdom.
P6-04-15 The effects of inhibitors of the signal transduction pathways on triple negative cells with stem characteristics
Yang H, Shi A, Xu N, Ou R, Ding Y, Wang H. The First Hospital of Jilin University, Changchun, Jilin, China. Hongmei Yang is a recipient of an Avon-AACR International Scholar-In-Training Award
P6-04-16 TGF-β2, a novel target of CD44-promoted breast cancer invasion
Al-Riyami H, Madani S, Gupta I, Shanmuganathan S, Abdraboh ME, Al-Farsi Y, Raj MHG, Ouhtit A. College of Medicine and Health Sciences, Sultan Qaboos University, Muscat; LSU Health Sciences Center, New Orleans, LA.
P6-04-17 The irreversible c-Jun N-terminal kinase (JNK) inhibitor, JNK-IN-8, sensitizes basal-like breast cancer cells to lapatinib
Ebelt ND, Van Den Berg CL. The University of Texas at Austin, Austin, TX.
P6-04-18 CD146 suppresses breast tumor invasion via its novel target gene, latexin
Gupta I, Fernando A, Gaur R, Shanmuganathan S, Raj MGH, Ouhtit A. College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman; LSU Health Sciences Center, New Orleans, LA.
P6-04-19 CD146/CD44: A novel pathway in breast cancer
Shanmuganathan S, Abdraboh ME, Hollenbach AD, Al-Farsi YM, Gupta I, Raj MHG, Ouhtit A. College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman; LSU Health Sciences Center, New Orleans, LA.
P6-04-20 A peptide-guided hydrophobically modified glycol chitosan (HGC) nanoparticles is very useful for targeting triple negative breast cancer
Park HY, Kim WW, Jung JH, Kim J-H, Bae SM, Lee B-H, Kang JG, Lee SJ, Choi HH, Lee YH, Kim I-S. Kyungpook National University, Daegu, Korea; Hyosung Hospital.
P6-04-21 Novel therapy of liver metastases of cancer using abraxane loaded into multi-stage nanovector
Tanei T, Liu X, Ferrari M, Godin B, Yokoi K. Methodist Hospital Research Institute, Houston, TX.
P6-04-22 Metformin is an effective drug to target the bevacizumab driven cancer stem cell stimulation in murine 4T1 breast cancer cell line
Antonio HMR, Sicchieri RD, Andrade JM, Tiezzi DG. Faculty of Medicine of Ribeirão Preto.
P6-04-23 Withdrawn
  Tumor Cell and Molecular Biology: Biomarkers
P6-05-01 Basal and induced receptor profiles cluster cell lines into subtypes and predict drug response in a panel of breast cancer lines
Schoeberl BM, Pace EA, Niepel M, Hafner M, Chai DH, Sorger PK. Merrimack Pharmaceuticals, Cambridge, MA; Harvard Medical School, Boston, MA.
P6-05-02 Molecular genetic grading in breast cancer: Development and validation of a prognostic marker
Matuschek C, Boelke E, Prisack HB, Budach W, Nestle-Krämling C, Gerber PA, Pagouras C, Bojar H. Heinrich Heine University, Duesseldorf, NRW, Germany; Institute for Molecular Oncology, Duesseldorf, NRW, Germany; Krankenhaus Gerresheim, Duesseldorf, NRW, Germany.
P6-05-03 Evaluation of predictive markers for clinical outcome after neoadjuvant radiochemotherapy in breast cancer
Matuschek C, Boelke E, Nestle-Krämling C, Speer V, Prisack H, Gerber PA, Bojar H, Audretsch W, Roth S, Budach W. Heinrich Heine University, Duesseldorf, NRW, Germany; Institute for Molecular Oncology, Duesseldorf, NRW, Germany; Krankenhaus Gerresheim, Duesseldorf, NRW, Germany; Marien Hospital (MHD), Duesseldorf, NRW, Germany.
P6-05-04 The prognostic significance of the methylation pattern in breast cancer and its relation to other biomarkers
Abdel Hamid TM, Bahnassy AA, Shafik HE, El Ghazaly HA, El Hussainy AM, Ali Eldin NH. NCI - Cairo University, Cairo, Egypt; Ain Shams University, Cairo, Egypt.
P6-05-05 Gene expression signatures of effector immune cell abundance are significantly associated with pathologic breast tumor response in the neoadjuvant setting
Alistar AT, Nagalla S, D'agostino RBJR, Chou JW, Black MA, Miller LD. Wake Forest School of Medicine, Winston Salem, NC; Thomas Jefferson University, Philadelphia, PA; Otago School of Medical Sciences, University of Otago, Dunedin, New Zealand.
P6-05-06 Association of HER2/neu single nucleotide polymorphism with trastuzumab-related cardiotoxicity
Chuang E, Stanton S, Ward MM, Christos P, Sanford R, Lam C, Cobham MV, Donovan D, Scheff R, Cigler T, Moore A, Vahdat LT, Lane ME. Weill Cornell Medical College, New York, NY.
P6-05-07 Discordance in estrogen receptor, progesterone receptor and HER-2/neu status between primary and metastatic breast cancer: A systematic review
Yeung IC, Clemons M, Haggar F, Addison C, Hutton B, Kuchuk I, Zhu X, Mazzarello S, Arnaout A. The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada; The Ottawa Hospital, Ottawa, ON, Canada; The Ottawa Hospital Research Institute, Ottawa, ON, Canada.
P6-05-08 Nuclear HER3 localisation plays a role in trastuzumab resistance in HER2-positive breast cancer
Hashimoto K, Roxanis I, Generali D, Andreis D, Strina C, Cappelletti M, Macaulay V, Kong A. Epidermal Growth Factor Receptors Group, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom; IGF Group, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom; Cellular Pathology, University of Oxford, Oxford, United Kingdom; Instituti Ospitalieri di Cremona, Cremona, Italy.
P6-05-09 Development of a predictive biomarker gene expression signature for the PIK3CA inhibitor, GDC-0032, in breast cancer cells
Savage H, O'Brien C, Spoerke J, Huw L, Wallin J, Friedman L, Lackner MR, Wilson TR. Genentech, South San Francisco, CA.
P6-05-10 Association between BRCA1/2 status and DNA-based assays for homologous recombination deficiency in breast cancer
Timms KM, Abkevich V, Neff C, Morris B, Potter J, Tran TV, Chen J, Sangale Z, Tikishvili E, Zharkikh A, Perry M, Gutin A, Lanchbury JS. Myriad Genetics, Inc., Salt Lake City, UT.
P6-05-11 Run-in phase of prospective WSG-ADAPT HR+/HER2- trial demonstrates feasibility of early endocrine sensitivity prediction by recurrence score and conventional parameters in clinical routine
Harbeck N, Gluz O, Kreipe HH, Christgen M, Svedman C, Shak S, Hofmann D, Kuemmel S, Nuding B, Rezai M, Schumacher C, Kusche M, Forstbauer H, Maass N, Kraemer S, Aktas B, Mohrmann S, Wuerstlein R, Kates RE, Nitz U. West German Study Group GmbH, Moenchengladbach, Germany; Breast Center of the University of Munich (LMU), Munich, Germany; Breast Center Niederrhein, Ev. Bethesda Hospital, Moenchengladbach, Germany; Institute of Pathology, Medical University Hannover, Hannover, Germany; Genomic Health, Inc., Redwood City; Clinics Essen-Mitte, Essen, Germany; Ev. Hospital Bergisch Gladbach, Bergisch Gladbach, Germany; Luisenhospital Duesseldorf, Duesseldorf, Germany; St. Elisabeth Hospital Cologne, Cologne, Germany; Marienhospital Aachen, Aachen, Germany; Oncologic Practive Network, Troisdorf, Germany; University Clinics Aachen, Aachen, Germany; University Clinics Cologne, Cologne, Germany; University Clinics Essen, Essen, Germany; University Clinics Duesseldorf, Duesseldorf, Germany.
P6-05-12 Comprehensive molecular analysis of estrogen receptor positive breast cancer to determine clinically actionable alterations
O'Brien C, Savage H, Huw L, Fumagalli D, Salgado R, Criscitello C, Pugliano L, Laios I, Piccart M, Michiels S, Sotiriou C, Loi S, Lackner MR, Wilson TR. Genentech, Inc, South San Francisco, CA; Jules Bordet Institute, Brussels, Belgium; Istituto Europeo di Oncologia, Milan, Italy; Institut Gustave Roussy, Villejuif, France; Peter MacCallum Cancer Center, East Melbourne, VIC, Australia.
P6-05-13 Tumor and cellular distribution of activated forms of ER and PR in breast cancers
Bonneterre J, Bosq J, Valent A, Gilles E, Zukiwski A. Centre Oscart-Lambret, Lille, France; Institut Gustave-Roussy, Villejuif, France; Invivis Pharmaceuticals, Bridgewater, NJ; Arno Therapeutics, Flemmington, NJ.
P6-05-14 Prognostic significance of Ki-67 index value at primary breast tumor in recurrent breast cancer
Nishimura R, Osako T, Nishiyama Y, Tashima R, Nakano M, Fujisue M, Toyozumi Y, Arima N. Kumamoto City Hospital, Kumamoto City, Kumamoto, Japan.
P6-05-15 Analysis of Ki-67 index on normal breast tissue of premenopausal women exposed to tamoxifen and raloxifene: A randomized, double-blind study
Da Silva BB, Lopes-Costa PV, Rosal MA, Gebrim LH. Federal University of Piauí, Teresina, Piauí, Brazil; Universidade Federal de São Paulo, São Paulo, Brazil.
P6-05-16 p53 and BCL2 expression across molecular subtypes: Correlation with disease progression, response to therapy and site of relapse in 1099 early breast cancer patients
Alessandra F, Irene T, Anna DB, Sabrina V, Elisa M, Cristiana E, Paola M, Simonetta B, Valentina D, Barbara A, Paola P, Cecilia N, Gianluigi F, Patrizia V, Letizia P, Claudio B, Franco DF, Francesco C, Marcella M. Regina Elena National Cancer Institute, Rome, Italy.
P6-05-17 A study of investigating biologic markers of anti-tumor effects of zoledronic acid and taxane-based chemotherapy for metastatic breast cancer in bone: A prospective, multi-center, non-randomized study (BEAT-ZO) (KCSG BR10-13)
Choi YJ, Bae JW, Kim HJ, Kang SY, Park YH, Lee S, Jung KH, Oh H-S, Choi IS, Lee K-H, Lee S-E, Park KH. Korea University College of Medicine, Seoul, Republic of Korea; Chung-Ang University Hospital; Severance Hospital, Yonsei University College of Medicine; Ajou University School of Medicine; Samsung Medical Center, Sungkyunkwan University School of Medicine; Asan Medical Center, University of Ulsan College of Medicine; Gangneung Asan Hospital, University of Ulsan College of Medicine; Seoul Municipal Boramae Hospital, Seoul National University College of Medicine; Cancer Research Institute, Seoul National University; Dong-A Medical Center.
P6-05-18 A53, cell cycle phenotype and Cdc7 kinase: Identifying patients likely to benefit from targeted Cdc7 therapy
Ian P, Leigh E, Fizza M, Kai S, Gareth WH, Richard S. UCL Cancer Institute, London, United Kingdom; Anglia Ruskin University, Cambridge, United Kingdom.
P6-05-19 Withdrawn
P6-05-20 Designing biomarker panels for pre- and post-menopausal breast cancer diagnostic testing using MSD technology
Henderson MC, Yeh T-F, Reese DE, Borman S, Hollingsworth A. Provista Diagnostics, Scottsdale, AZ; Provista Diagnostics, New York, NY; Mercy Women's Center, Oklahoma City, OK.
P6-05-21 High standardized uptake value of 18F-fluorodeoxy-glucose positron emission tomography is related with FOXM1 expression, which negatively influences survival in breast cancer patients
Ahn SG, Lee HM, Lee HW, Lee SA, Leem S-H, Jeong J, Chu I-S. Yonsei University College of Medicine, Seoul, Korea; Eulji University College of Medicine, Seoul, Korea; Dong-A University, Busan, Korea; Korea Research Institute of Bioscience and Biotechnology, Daejon, Korea.
P6-05-22 Young-onset breast cancer exhibits a more aggressive tumor biology
Cabioglu N, Bozdogan A, Eren-Boler D, Kara H, Karayagiz H, Uras C. Faculty of Medicine, Acibadem University, Istanbul, Turkey; Acibadem Maslak Hospital, Istanbul, Turkey; Acibadem Aile Hospital, Istanbul, Turkey.
P6-05-23 An immunohistochemical study of folate receptor alpha status in breast cancers in Asian vs. North American women
Tacha D, Hoang LL, Bremer RE, Walshe J. Biocare Medical LLC, Concord, CA.
P6-05-24 Expression of aquaporin 5 and its polymorphisms predict survival in patients with early breast cancer
Lee SJ, Chae YS, Park HY, Jung JH, Kim WW, Park J-Y, Jeong JY. Kyungpook National University Medical Center, Daegu, Korea; Kyungpook National University Medical Center, Daegu; Kyungpook National University Medical Center.
P6-05-25 Ratio of notch receptors is critical for response to notch inhibition by a gamma-secretase inhibitor in triple negative breast cancer cells
Zlobin A, Kuprys-Olsauskas R, Shah D, Osipo C. Loyola University Chicago, Maywood, IL.
P6-05-26 BORIS: A potential novel breast cancer biomarker
Apte A, Chandrasekharan S, Klenova E. Essex County Hospital, CHUFT, Colchester, Essex, United Kingdom; University of Essex, Colchester, Essex, United Kingdom.
P6-05-27 p53, c-Myc and EGFR protein interactions confer worse prognosis in patients with triple negative breast cancer (TNBC)
Lakis S, Koletsa T, Kostopoulos I, Papadimitriou C, Skarlos D, Koutras A, Res E, Matsiakou F, Linardou H, Kotoula V, Fountzilas G. Hellenic Cooperative Oncology Group (HeCOG), Athens, Greece.
P6-05-28 Nicastrin RNA in situ hybridization (RNAScope®) reveals estrogen receptor negative breast cancer patients at risk of metastatic relapse and could serve as companion diagnostic for anti-nicastrin monoclonal antibody therapy
Filipovic A, Green A, Hsu R, Su N, Rahka E, Coombes RC. Imperial College London, London, United Kingdom; University of Nottigham, Nottingham, United Kingdom; Advanced Cell Diagnostics, Hayward, CA.
  Prognosis and Response Prediction: Prognostic and Predictive Factors – General
P6-06-01 Improved outcomes with occult versus known primary breast cancer: A SEER analysis
Chaudhry H, Mahmood U, Hanlon A, Bao T, Chumsri S, Tkaczuk K, Kesmodel S, Bellavance E, Feigenberg S. The George Washington University School of Medicine, Washington, DC; MD Anderson, Houston, TX; School of Nursing, University of Pennsylvania, Philadelphia, PA; University of Maryland, Baltimore, MD. Huma Elahi Chaudhry is a recipient of an SABCS Clinical Scholars scholarship
P6-06-02 Direct comparison of risk classification between MammaPrint®, Oncotype DX® and MammoStrat® assays in patients with early stage breast cancer
Shivers SC, Clark L, Esposito N, Howard N, King J, Acs G, Ellis D, Vrcelj V, Zanchi A, Stork-Sloots L, de Snoo F, Baehner FL, Butler SM, Jamshadian F, Sing AP, Blumencranz PW, Cox CE. University of South Florida, Tampa, FL; Florida Hospital Tampa, Tampa, FL; Morton Plant Hospital, Clearwater, FL; Agendia NV, Amsterdam, Netherlands; Genomic Health Inc., Redwood City, CA.
P6-06-03 Differing patterns of treatment effect in a trial assessing sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT)
A'Hern R, Gillett C, Pinder S, Kalaitzaki E, Bliss J, Tutt A, Barrett-Lee P, Ellis P, Johnston S. The Institute of Cancer Research, Sutton, Surrey, United Kingdom; Guy's Hospital, Kings Health Partners AHSC, London, United Kingdom; Velindre NHS Trust, Cardiff, United Kingdom; Royal Marsden NHS Trust, London, United Kingdom.
P6-06-04 Breast cancer in young women: Have the prognostic and predictive implications of breast cancer subtypes changed over time?
Wilson S, Tyldesley S, Speers C, Bernstein V, Voduc D, Gelmon K, Chia S. British Columbia Cancer Agency, Vancouver, BC, Canada.
P6-06-05 RadiotypeDx: Identification and validation of a radiation sensitivity signature in human breast cancer
Speers C, Balbin OA, Liu M, Alluri P, Pierce L, Feng F. University of Michigan, Ann Arbor, MI. Corey W. Speers is a recipient of an AACR Scholar-In-Training Award
P6-06-06 Family history and young breast cancer patients in the UK: The POSH study
Copson ER, Cutress RI, Eccles BK, Maishman T, Stanton L, Eccles DM. Cancer Sciences Academic Unit and University of Southampton Clinical Trials Unit, Southampton, United Kingdom.
P6-06-07 5-year disease free-survival results of aggressively-treated breast cancer during pregnancy: Results from a French multicenter study
Vanlemmens L, Delaloge S, Ploquin A, Bachelot T, Frenel J-S, Loustalot C, Kerbrat P, Mignot L, Debled M, Allouache D, Vinceneux-Confavreux A, Provansal M, Dalenc F, Mouret-Reynier M-A, Lerebours F, Jacot W, Tartas S, Morvan F, Jebert S, Decoupigny E, Rouzier R. Centre Oscar Lambret, Lille, France; Institut Gustave Roussy, Villejuif, France; Centre Léon-Bérard, Lyon, France; Centre René Gauducheau, Saint Herblain Cedex, France; Centre Georges-François Leclerc, Dijon, France; Centre Eugène-Marquis, Rennes, France; Institut Bergonie, Bordeaux, France; Institut Curie, Paris, France; Centre François Baclesse, Caen, France; CHRU, Tours, France; Institut Paoli-Calmettes, Marseille, France; Institut Claudius Regaud, Toulouse, France; Centre Jean- Perrin, Clermont-Ferrand, France; CRLC Val d'Aurelle, Montpellier, France; Centre René Huguenin, Saint-Cloud, France; CHU, Lyon, France; Centre Hospitalier, Pontoise, France.
P6-06-08 Impact of initial surgical treatment delay on survival according to hormone responsiveness in breast cancer
Yoo T-K, Han W, Moon H-G, Kim J, Lee JW, Kim MK, Lee E, Kim J, Noh D-Y. Seoul National University College of Medicine, Seoul, Republic of Korea.
P6-06-09 Baseline assessment of left ventricular function for breast cancer patients undergoing anthracycline and/or trastuzumab: What is the prevalence of baseline dysfunction?
Abu-Khalaf MM, Medic I, Hatzis C, Park E, Chung G, DiGiovanna M, Hofstatter E, Sanft T, Pusztai L, Gross C, Russell K, Russell R. Yale University School of Medicine; Yale Cancer Center, New Haven, CT; Norwalk Hospital, Norwalk, CT; Yale University School of Medicine, New Haven, CT; Yale University School of Medicine, Yale COPPER Center, New Haven, CT.
P6-06-10 Prognostic role of Ki67 determined on metastatic biopsies in patients with advanced breast cancer
Falato C, Lorent J, Kessler L, Karlsson E, Wilking U, Wright P, Skoog L, Bergh J, Foukakis T. Karolinska Institutet, Stockholm, Sweden; Central Manchester University Hospitals NHS Foundation Trust, Manchester, United Kingdom.
P6-06-11 The Will Rogers phenomenon in breast cancer – How does the change from AJCC 5th edition to AJCC 6th edition affect cancer survival?
Ng CH, Bhoo Pathy N, See MH, Tan GH, Teh YC, Taib NA, Yip CH. University Malaya Medical Centre, Kuala Lumpur, Malaysia.
P6-06-12 Prognostic significance of pretreatment neutrophil/-lymphocyte ratio in breast cancer: A meta-analysis
Al-Mubarak M, Templeton AJ, Vera-Badillo FE, Ocana A, Seruga B, Amir E. Princess Margaret Cancer Centre and University of Toronto, Toronto, ON, Canada; Albacete University Hospital, Albacete, Spain; Institute of Oncology Ljubljana, Ljubljana, Slovenia.
P6-06-13 Optimized prediction of clinical outcome by the PREDICT plus tool and the 70-gene signature in early stage node-negative breast cancer
Drukker CA, Nijenhuis MV, Bueno-de-Mesquita JM, Retel VP, van Tinteren H, Schmidt MK, van Harten WH, Sonke GS, van 't Veer LJ, Rutgers EJ, van de Vijver MJ, Linn SC. Netherlands Cancer Institute, Amsterdam, Netherlands; University of California San Francisco, San Francisco.
P6-06-14 Weight gain and educational level are strongly associated with breast cancer prognosis. Findings from the prospective SU.VI.MAX study
Zelek L, Touvier M, Galan P, Hercberg S. Assistance Publique Hôpitaux de Paris, CHU Avicenne, Bobigny, France; INSERM/ U1125 INRA/ CNAM/ Université Paris 13, Bobigny, France.
P6-06-15 Cost impact of oncotype Dx® breast cancer assay use in a fully integrated healthcare delivery system
Carlson JJ, Watanabe J, Boudreau D. University of Washington; Group Health Research Institute; Western University of Health Sciences College of Pharmacy.
P6-06-16 Young age as a good prognostic factor in de novo metastatic breast cancer
Lee GE, Dawood S, Haaland BA, Tan PS, Bhoo-Pathy N, Dent RA. National Cancer Centre Singapore, Singapore, Singapore; Dubai Health Authority, Dubai, United Arab Emirates; DUKE-NUS Graduate Medical School, Singapore, Singapore; University of Malaya, Kuala Lumpur, Malaysia.
P6-06-17 Gene signature model predicts metastatic onset better than standard clinical markers – Nested case-control design uniquely enables enrichment for biologically relevant features
Lindstrom LS, Jauhiainen A, Wilking U, Foukakis T, Åström G, Czene K, Bergh J. University of California at San Francisco (UCSF), San Francisco, CA; Karolinska Institutet, Stockholm, Sweden; Uppsala University, Uppsala, Sweden.
P6-06-18 Type 2 diabetes trends to be associated with poor prognosis in triple negative breast cancer patients
Liu Z-B, Ma F-J, Qu L, Shen Z-Z, Shao Z-M, Liu G-Y. Shanghai Cancer Center Fudan University, Shanghai, China; ZheJiang Hospital, Hangzhou, China.
P6-06-19 Impact of hospital surgical volume on breast cancer mortality: A population based study in the Netherlands
Siesling S, Tjan-Heijnen VCG, de Roos M, Snel YEM, van Dalen T, Wouters MW, Struikmans H, Maduro JH, van der Hoeven KJM, Visser O. Comprehensive Cancer Center the Netherlands, Utrecht, Netherlands; University of Twente, Enschede, Netherlands; Maastricht University Medical Centre, Maastricht, Netherlands; Rivierenland Hospital, Tiel, Netherlands; Association of General Hospitals, Utrecht, Netherlands; Diakonessen Hospital, Utrecht, Netherlands; Netherlands Cancer Institute, Amsterdam, Netherlands; Medical Centre Haaglanden, The Hague, Netherlands; Leiden University Hospital, Leiden, Netherlands; University Medical Centre Groningen, Groningen, Netherlands.
P6-06-20 Predictive factors for pathologic complete response and disease-free survival after neoadjuvant chemotherapy with trastuzumab: A multicenter retrospective observational study in patients with HER2-positive primary breast cancer (JBCRG-C03 study)
Takada M, Ishiguro H, Nagai S, Ohtani S, Kawabata H, Yanagita Y, Hozumi Y, Shimizu C, Takao S, Sato N, Kosaka Y, Sagara Y, Iwata H, Ohno S, Kuroi K, Masuda N, Yamashiro H, Sugimoto M, Kondo M, Naito Y, Sasano H, Inamoto T, Morita S, Toi M. Kyoto University Hospital, Kyoto, Japan; Kyoto University Hospital; Saitama Cancer Center; Hiroshima City Hospital; Toranomon Hospital; Gunma Prefectural Cancer Center; Jichi Medical University Hospital; National Cancer Center Hospital; Hyogo Cancer Center; Niigata Cancer Center Hospital; Kitasato University School of Medicine; Social Medical Corporation Hakuaikai, Sagara Hospital; Aichi Cancer Center; Clinical Cancer Center, National Kyushu Cancer Center; Tokyo Metropolitan Cancer and Infectious Diseases Centre, Komagome Hospital; Osaka National Hospital; National Hospital Organization Kure Medical Center; Institute for Advanced Biosciences, Keio University; Faculty of Medicine, University of Tsukuba; Keio University; Tohoku University Hospital and School of Medicine; Faculty of Health Care, Tenri Health Care University; Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital; Graduate School of Medicine, Kyoto University.
P6-06-21 A 5-gene predictor of triple negative breast cancer outcome that also correlates with immune checkpoint receptor expression
Yau C, Campbell M, Esserman L, Benz CC. Buck Institute for Research on Aging, Novato, CA; University of California, San Francisco, CA.
P6-06-22 Outcome of patients with intrinsic hypersensitivity to ionizing radiation and included in the COHORT phase II randomized trial evaluating concurrent or sequential letrozole with adjuvant breast radiotherapy
Azria D, Lemanski C, Gourgou-Bourgade S, Romieu G, Gutowski M, Jacot W, Fenoglietto P, Ozsahin M, Bourgier C. ICM, Montpellier, France; CHUV, Lausanne, Switzerland.
P6-06-23 Glycogen-rich, clear cell breast cancer – An underestimated histopathological risk factor?
Kern PA, von Minckwitz G, Rietkoetter E, Kimmig R, Rezai M, Otterbach F. University Hospital of Essen, Essen, North-Rhine Westfalia, Germany; Breast Center Düsseldorf, Düsseldorf, North-Rhine-Westfalia, Germany; GermanBreastGroup, Neu-Isenburg, Hessen, Germany; Institute of Pathology, Soest, North-Rhine Westfalia, Germany.
P6-06-24 Intact p53 can predict more hormonal therapy benefit in invasive breast cancer: Evaluation of interactions between immunohistochemical p53 status and adjuvant therapy
Lee JW, Kim HJ, Son BH, Ahn SH. University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.
P6-06-25 Usefulness of pretreatment NLR as prognostic factor of late recurrence, 5-year after primary treatment
Noh H, Lee J, Choi E, Han A. Wonju College of Medicine, Yonsei University, Wonju-si, Gangwon-do, Korea. Hany Noh is a recipient of an Avon-AACR International Scholar-In-Training Award
P6-06-26 St Gallen molecular subtypes adds prognostic information beyond detection by screening mammography
Rydén L, Falck A-K, Fernö M, Bendahl P-O. Clinical Sciences in Lund, Lund, Sweden; Clinical Sciences in Lund, Div of Oncology, Lund, Sweden.
P6-06-27 Expression of ATP-binding cassette transporter C1 (ABCC1) and activated sphingosine kinase 1 in breast cancer are associated with significantly shorter disease free survival
Yamada A, Nagahashi M, Aoyagi T, Kida K, Milstien S, Spiegel S, Ishikawa T, Endo I, Takabe K. Virginia Commonwealth University, Richmond, VA; Yokohama City University Medical Center, Yokohama, Kanagawa, Japan; Yokohama City University School of Medicine, Yokohama, Kanagawa, Japan.
P6-06-28 Survival gain in patients with de novo metastatic breast cancer in past two decades is largely attributable to treatment
Bhoo-Pathy N, Verkooijen HM, Tan E-Y, Hui M, Taib NA, Brand JS, Dent R, See M-H, Subramaniam S, Chan PMY, Lee S-C, Hartman M, Yip C-H. National Clinical Research Centre, Malaysia; University of Malaya, Malaysia; National University of Singapore, Singapore; Tan Tock Seng Hospital, Malaysia; Karolinska Institute, Sweden; National Cancer Center Singapore, Singapore.
P6-06-29 Single progesterone receptor positive (PgR+) is a predictive marker for endocrine therapy but not a prognostic factor in ER-/PgR+/HER2- breast cancers
Fan Y, Ding XY, Xu BH, Wang JY, Ma F, Yuan P, Li Q, Zhang P, Luo Y. Cancer Hospital&Institute, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. Ying Fan is a recipient of an Avon-AACR International Scholar-In-Training Award
P6-06-30 Are synchronous and metachronous bilateral breast cancers different? An immunohistochemical analysis aimed at intrinsic tumor phenotype
Senkus E, Szade J, Pieczynska B, Zaczek A, Pikiel J, Sosinska-Mielcarek K, Karpinska A, Jassem J. Medical University of Gdank, Gdansk, Poland; Medical University of Gdansk, Gdansk, Poland; Laboratory of Cell Biology, Intercollegiate Faculty of Biotechnology, University of Gdansk and Medical University of Gdansk, Gdansk, Poland; Regional Oncology Center, Gdansk, Poland; West-Pomeranian Oncology Center, Szczecin, Poland.
P6-06-31 Prognostic factors and outcomes in triple negative breast cancer - A single institution experience
Apuri S, Sun W, Bardhan P, Minton S, Soliman H, Han HS, Lee J-H, Fulp W, Ismail-Khan R. H. Lee Moffitt Cancer Center, Tampa, FL; Wake Forest School of Medicine, Winston-Salem, NC.
P6-06-32 4EVER: Does mTOR inhibition have a major clinical impact on bone health in postmenopausal women with hormone receptor positive (HR+) locally advanced breast cancer treated with everolimus (EVE) in combination with exemestane (EXE)?
Hadji P, Tesch H, Fasching PA, Lueftner DI, Janni W, Lux MP, Schneeweiss A, Decker T, Belleville E, Kreuzder J, Muth M, Wallwiener D. University Hospital of Giessen and Marburg GmbH, Marburg, Germany; Onkologische Gemeinschaftspraxis am Bethanien-Krankenhaus, Frankfurt/Main, Germany; University Breast Centre for Franconia, Erlangen, Germany; Charité University Medicine, Campus Benjamin Franklin, Berlin, Germany; University of Ulm, Ulm; National Center for Tumor Diseases, Heidelberg, Germany; Onkologie Ravensburg, Ravensburg, Germany; Novartis Pharma GmbH, Nuernberg, Germany; ClinSol GmbH & Co KG, Wuerzburg, Germany; University of Tuebingen, Tuebingen, Germany.
P6-06-33 Risk factors for the development of toxicity during chemotherapy in breast cancer patients based on the presence of BRCA1/2 mutation
Huszno J, Nowara E. Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch, Gliwice, Poland.
P6-06-34 Comparing recurrence risk scores derived from 4 immunohistochemistry stains (IHC4) versus oncoType DX
Miller DV, Jensen TA, Covington AD, Rosenthal R, Avent JM, Hansen J, Peck L, Wise PD, Leavitt MO, Wallentine JC, Rowley B. Intermountain Healthcare, Salt Lake City, UT.
P6-06-35 Invasive lobular cancer versus mixed invasive lobular cancer with invasive ductal cancer: 20 year outcomes at one institution
Wallace AS, Xiang D, Hockman L, Arya M, Jeffress J, Wang Z, Dale PS. University of Missouri, Columbia; Creighton University.
P6-06-36 Clinical characteristics and long-term outcomes of patients with invasive lobular carcinoma at one institution
Wallace AS, Dale PS, Arya M, Hockman L, Jeffress J, Wang Z, Xiang D. University of Missouri, Columbia; Creighton University.
P6-06-37 Predicting improvements in survival based on improvements in pathologic response rate to neoadjuvant chemotherapy in different breast cancer subtypes
Hatzis C, Gould RE, Zhang Y, Abu-Khalaf M, Chung G, Sanft T, Hofstatter E, DiGiovanna M, Shi W, Chagpar A, Symmans WF, Pusztai L. Yale University Cancer Center, New Haven, CT; MD Anderson Cancer Center, Houston, TX.
P6-06-38 Withdrawn
P6-06-39 Chest wall invasion is a more significant prognostic factor than nodal spread, triple-negative or Her2 receptor status in stage III breast cancer: A large, single institution retrospective analysis
Ansley KC, Batten KG, Singel SM. The University of Texas Southwestern Medical Center, Dallas, TX.
P6-06-40 Analysis of outcome according to risk factors in the randomized phase III TURANDOT trial evaluating first-line bevacizumab-containing therapy for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)
Brodowicz T, Pienkowski T, Beslija S, Melichar B, Lang I, Inbar MJ, Anghel R, Spanik S, Ahlers S, Zielinski C. Medical University of Vienna and Central European Cooperative Oncology Group (CECOG), Vienna, Austria; Postgraduate Medical Center, Warsaw, Poland; Institute of Oncology, Sarajevo, Bosnia and Herzegowina; Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic; National Institute of Oncology, Budapest, Hungary; Tel Aviv Sourasky Medical Centre, Tel Aviv, Israel; University of Medicine and Pharmacy, Bucharest, Romania; Onkol. Ustav Sv. Alzbety, Bratislava, Slovakia (Slovak Republic); IST GmbH, Mannheim, Germany.
P6-06-41 Non-palpable tumor is a surrogate factor for longer disease free survival in early breast cancer: Evaluation of a 23 years-Venezuelan cohort
Contreras AC, Acosta V, Torres LG, Ferri N, López H, Marin E, Juan P, Gil ME, Pinto JA, Flores CF, Gómez HL. Centro Médico Dr. Rafael Guerra Méndez, Valencia, Estado Carabobo, Venezuela; CECLINES, Caracas, Venezuela; Clínica El Viñedo, Valencia, Estado Carabobo, Venezuela; Universidad de Carabobo, Valencia, Estado Carabobo, Venezuela; División de Investigación, Oncosalud-Auna, Lima, Peru; Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru.
P6-06-42 Impact of molecular subtype on overall survival according to age in Korean women
Lee A, Woo J, Yun C, Min SY, Kim Y, Yu S, Lim W, Paik N-S, Moon B-I. Ewha Womans University Hospital, Seoul, Korea.
P6-06-43 Clinicopathological features of breast cancer patients with late recurrences
Murata T, Takahashi M, Hayashida T, Jinno H, Kitagawa Y. Keio University School of Medicine, Tokyo, Japan.
P6-06-44 Role of uPA and PAI-1 mRNA expression as prognostic factors in molecular subtypes of breast cancer
Witzel I, Milde-Langosch K, Schmidt M, Karn T, Rody A, Wirtz R, Jänicke F, Müller V. University Medical Center, Hamburg, Germany; University Hospital, Mainz, Germany; University Hospital, Frankfurt, Germany; Stratifyer Molecular Pathology GmbH, Cologne, Germany; University Medical Center Schleswig-Holstein, Luebeck, Germany.
P6-06-45 Predictive significance of the mucocutaneous toxicities, but not dose intensity of capecitabine for the treatment of lapatinib plus capecitabine in patients with HER2 positive metastatic breast cancer
Araki K, Fukada I, Takahashi S, Ito Y. Cancer Institute Hospital - The Cancer Institute of the Japanese Foundation for Cancer Research, Koto-Ku, Tokyo, Japan.
P6-06-46 Treatment decisions and five year outcomes of the oncotype Dx test: An independent assessment
Bhargava R, Brufsky AM, Lembersky BC, Jankovic R, Puhalla SL, Oesterreich S, Lee A, Dabbs DJ. Magee-Women's Hospital of UPMC, Pittsburgh, PA, Uganda.
P6-06-47 The association between EGFR and cMET expression and phosphorylation and its prognostic implication in patients with breast cancer
Chae YK, Qi Y, Sohn J, Chen H, Hortobagyi GN, Gonzalez-Angulo AM. University of Texas MD Anderson Cancer Center, Houston, TX.
P6-06-48 Breast cancer subtypes and metastatic pattern at the Regional Breast Center Dresden
Kast K, Link T, Friedrich K, Petzold A, Niedostatek A, Werner C, Werner A, Baretton GB, Klug SJ, Wimberger P. University Hospital Carl Gustav Carus, Technical University of Dresden, Germany; Institute of Pathology, University Hospital Carl Gustav Carus, Technical University of Dresden, Germany; Regional Clinical Cancer Registry, Technical University of Dresden, Germany; Diakonissenkrankenhaus Dresden, Germany.
P6-06-49 Predictive value of EZH2 and its associated genes as a prognostic signature of breast cancer
Kim S-K, Leem S-H, Ahn SG, Jeong J, Chu I-S. Medical Genomics Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, Korea; Dong-A University, Busan, Korea; Gananam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea; Korean Bioinformation Center, Korea Research Institute of Bioscience and Biotechnology, Deajeon, Korea.
P6-06-50 Obesity and the influence on tumor biology as determined by the intermediate risk 21-gene recurrence scores (RS) and the 70-gene breast cancer recurrence signature (70-GS) assay
Robinson P, Mai H, Guo R, Gaynor E, McCroskey Z, Ersahin C, Albain K, Lo S. Loyola University Medical Center, Maywood, IL.
P6-06-51 Multivariate analysis of factors effecting overall survival in minority based population of breast cancer patients receiving neoadjuvant chemotherapy: A single institution experience
Shah M, Jain S, Abhijai S. Stroger Hospital of Cook County, Chicago, IL.
P6-06-52 Increased expression of insulin-like growth factor-1 receptor is associated with better prognosis in a cohort of tamoxifen treated women
Aaltonen KE, Olsson H, Rosendahl AH, Malmström P, Hartman L, Fernö M. Clinical Sciences Lund, Lund University, Skåne University Hospital, Lund, Sweden.
P6-06-53 Ki67 labelling index (Ki67LI) can subdivide homogeneous HER2 negative luminal grading groups (HNL-GG) in distinct biological entities
Ferro A, Russo LM, Eccher C, Triolo R, Barbareschi M, Caldara A, Dipasquale M, Galligioni E. Santa Chiara Hospital, Trento, Italy; FBK, Trento, Italy.
P6-06-54 Analysis of treatment and survival of pathologic occult breast cancer with axillary lymph node metastasis: Nationwide retrospective study
Sohn G, Son BH, Baek S, Lee S, Lee Y, Kim HJ, Ko BS, Yu J, Lee JW, Ahn S-H. Asan Medical Center, Seoul, Korea.
P6-06-55 GSTT1, GSTM1, and ERCC1 rs3212986 genetic variants are associated with survival in previous untreated metastatic breast cancer
Zhang J, Liu Y, Wang Z. Fudan University Shanghai Cancer Center, Shanghai, China; Institutes of Biomedical Sciences, Fudan University, Shanghai, China.
P6-06-56 Emergency room visits and hospital admission rates after curative chemotherapy for breast cancer. A retrospective single center experience
Pittman NM, Mates M, Hopman WM. KGH Cancer Centre of Southeastern Ontario, Kingston, ON, Canada; KGH Clinical Research Centre, Kingston, ON, Canada.
P6-06-57 Progesterone receptor status and Ki-67 index may predict early relapse in luminal B/HER2 negative breast cancer patients
Zong Y, Zhu L, Wu J, Chen X, Huang O, Fei X, He J, Chen W, Li Y, Shen K. Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China; Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
  Psychosocial, Quality of Life, and Educational Aspects: Cost-Effectiveness
P6-07-01 Are patient perceptions and expectations about peri-operative imaging for metastatic breast cancer in keeping with current guidelines?
Simos D, Hutton B, Mazzarello S, Graham I, Caudrelier J-M, Gertler S, Wheatley-Price P, Segal-Nadler R, Verma S, Song X, Kuchuk I, Clemons M. The Ottawa Hospital Cancer Centre and University of Ottawa, Ottawa, ON, Canada; The Ottawa Hospital Centre for Practice Changing Research and University of Ottawa, Ottawa, ON, Canada; The Ottawa Hospital Cancer Centre, Ottawa, ON, Canada; The Ottawa Hospital Centre for Practice Changing Research and The Ottawa Hospital Research Institute, Ottawa, ON, Canada.
P6-07-02 Pharmacoeconomic evaluation of denosumab for the treatment of bone metastases in patients with advanced breast cancer in Canada
Habib MJ, Risebrough N, Moore P, Kendall R, Li CM, Goeree R. Amgen Canada, Mississauga, ON, Canada; Oxford Outcomes an ICON PLC Company, Toronto, ON, Canada; PATH Research Institute, St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada.
P6-07-03 Cost-effectiveness of molecular profiling for adjuvant decision making for patients with node negative breast cancers
Saghatchian M, Marguet S, Lueza B, Delaloge S, Bonastre J. Institut Gustave Roussy, Villejuif, France.
P6-07-04 Quality of care in post-screening pathways: 9-year evaluation of a national pilot one stop breast unit (OSBU)
Delaloge S, Fontenay R, Boinon D, Balleyguier C, Garbay J-R, André F, Mazouni C, Borget I, Rivera S, Chaurin P, Saghatchian M, Canale S, Bonastre J, Vielh P. Institut Gustave Roussy, Villejuif, France.
P6-07-05 Regional variation in Medicare expenditures for older women with localized breast cancer
Xu X, Soulos PR, Herrin J, Ross JS, Saraf A, Roberts KB, Killelea BK, Wang S, Long JB, Wang R, Ma X, Gross CP. Yale University School of Medicine, New Haven, CT; Health Research & Educational Trust, Chicago, IL; Yale University School of Public Health, New Haven, CT.
P6-07-06 Primary prophylaxis of febrile neutropenia during adjuvant docetaxel and cyclophosphamide (TC) chemotherapy for breast cancer
Yu JL, Kurin M, Pasetka M, Kiss A, Chan K, Sridhar SS, Warner E. Sunnybrook Odette Cancer Centre, Toronto, ON, Canada; Institute for Clinical Evaluative Sciences, Toronto, ON, Canada; Princess Margaret Cancer Centre, Toronto, ON, Canada.
P6-07-07 Febrile neutropenia primary prophylaxis with granulocyte-colony stimulating factors (G-CSF) in breast cancer
Younis T, Rayson D, Skedgel C. Dalhousie University, Halifax, NS, Canada; Atlantic Clinical Cancer Research Unit (ACCRU) at the Queen Elizabeth II Health Sciences Centre, Halifax, NS, Canada.
P6-07-08 Comparative cost-effectiveness analysis of mammostrat versus oncotype Dx to guide treatment decisions with adjuvant chemotherapy in early-stage breast cancer
Mislick K, Schonfeld W, Bodnar C, Tong KB. UCLA Pathology and Laboratory Medicine, Los Angeles, CA; Quorum Consulting, Inc., San Francisco, CA; GE Healthcare, Chalfont St Giles, United Kingdom.
P6-07-09 What should be done after PHARE and HERA? Using value of information analysis as a guide
Conter HJ. University of Texas, M.D. Anderson Cancer Center, Houston, TX.
P6-07-10 Healthcare resource used in metastatic HER2+ breast cancer patients initiating an oral anticancer treatment
Espie M, Lortholary A, Woronoff-Lemsi M-C, Flinois A, Chabernaud H, Dramard-Goasdoue M-H, Benjamin L, Merrouche Y. Hôpital Saint-Louis, Paris, France; Centre Catherine de Sienne, Nantes, France; CHRU de Besancon, Besancon, France; Kantar Health, Montrouge, France; Laboratoire GlaxoSmithKline, Marly-le Roi, France; Institut de Cancérologie Lucien Neuwirth, Saint Priest en Jarez, France.
P6-07-11 Health economic impact of breast cancer index (BCI) for late disease management in patients with estrogen receptor-positive, node-negative breast cancer
Gustavsen G, Schroeder BE, Kennedy P, Pothier K, Erlander MG, Schnabel CA. Health Advances, LLC, Weston, MA; bioTheranostics, Inc., San Diego, CA.
P6-07-12 Should adjuvant zoledronic acid be used in early-stage, endocrine-sensitive breast cancer?
Lamond NWD, Skedgel C, Rayson D, Younis T. Dalhousie University, Halifax, NS, Canada; Atlantic Clinical Cancer Research Unit, Halifax, NS, Canada.
  Psychosocial, Quality of Life, and Educational Aspects: Social and QOL Aspects – Other
P6-08-01 Analysis of patient-reported outcomes following nipple-sparing mastectomy and implant reconstruction
Pharmer LA, Koslow SB, Martins D, Theodore R, Christos PJ, Talmor M, Simmons RM, Tousimis E, Swistel AJ. Weill Cornell Medical College, New York, NY; New York Presbyterian Hospital-Weill Cornell Medical Center, New York, NY; MedStar Georgetown University Hospital, Washington, DC.
P6-08-02 Quality of life in breast cancer patients after breast conservation surgery or modified radical mastectomy - A comparative study from a tertiary cancer care center in India
Pudumjee SB, Mane AD, Deshmukh SP, Bokil KP, Choudhary AG, Sane SP. Ruby Hall Clinic - Kamalnayan Bajaj Cancer Center, Pune, Maharashtra, India.
P6-08-03 Incidence of winged scapula after breast cancer surgery with axillary dissection – Preliminary results
Nazário ACP, Rizzi SKLA, Simão CAH, Facina G. Universidade Federal de São Paulo, São Paulo, Brazil.
P6-08-04 Prognostic significance of quality-of-life scores in early stage and relapsed breast cancer: Results from seven randomized trials of the International breast cancer study group
Lee CK, Coates AS, Hudson M, Ribi K, Bernhard J. University of Sydney NHMRC Clinical Trials Centre, Sydney, NSW, Australia; International Breast Cancer Study Group, Bern, Switzerland.
P6-08-05 Discerning clinical relevance of biomarkers in early stage breast cancer
Smith ML, Railey E, White CB, Schneider BP. Research Advocacy Network, Plano, TX; Carol B. White & Associates, Evanston, IL; Indiana University, Simon Cancer Center, Indianapolis, IN.
P6-08-06 Sexual function, sexual activity and quality of life in women with breast cancer
Beutel B, Schrof I, Rita H, Lehmann K, Kullmann V, Alexander T, Herbert S, Andreas DB. HSK, Dr. Horst Schmidt Klinik, Wiesbaden, Hessen, Germany; Kliniken Essen Mitte, Essen, Nordrhein-Westfalen, Germany; University Medical Center, Johannes Gutenberg-University, Mainz, Rheinland-Pfalz, Germany.
P6-08-07 Out-of-pocket spending, dermatologic quality of life, and treatment satisfaction in breast cancer radiotherapy patients
Green S, Montgomery GH, Mattson DMK, Hydeman J, Schnur JB. Icahn School of Medicine at Mount Sinai, New York, NY; Roswell Park Cancer Institute, Buffalo, NY.
P6-08-08 Adjuvant breast cancer therapy: Correlation of treatment data with patient reported outcomes in a German breast cancer centre
Feiten S, Dünnebacke J, Heymanns J, Köppler H, Thomalla J, van Roye C, Wey D, Weide R. Institute for Health Care Research in Oncology, Koblenz, Rhineland-Palatinate, Germany; Breast Cancer Centre Marienhof, Koblenz, Rhineland-Palatinate, Germany; Oncology Group Practice Koblenz, Koblenz, Rhineland-Palatinate, Germany.
P6-08-09 A national survey on oncology clinicians' recommendations and knowledge of contraception for women with cancer
Giordano SB, York SL, Gosiengfiao Y, Smith K, Kiley J. Northwestern University, Chicago, IL; Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL.
P6-08-10 Breast cancer in young women in Canada: A needs assessment
Gordon A, DeCoteau M. Rethink Breast Cancer, Toronto, ON, Canada.
P6-08-11 Count us, know us, join us global survey: Comparing the feelings and needs of advanced breast cancer patients in the United States with patients in Latin America, Europe, and Asia
Miller H, Percassi D. CancerCare, New York, NY; Harris Interactive, Inc., Rochester, NY.
P6-08-12 Gains in women's education has not led to commensurate gains in seeking health-care early in breast cancer patients in urban India
Raghavan R, Alexander A, Prabhu J, Korlimarla A, Correa M, Raman N, Prasad M, Manjunath S, Shivananda S, Gopinath K, Srinath B, Sridhar T. St. John's Research Institution, Bangalore, Karnataka, India; St. John's Medical College & Hospital, Bangalore, Karnataka, India; St. John's Medical College, Bangalore, Karnataka, India; Sri Shankara Cancer Hospital & Research Centre, Bangalore, Karnataka, India; Sri Rangadore Memorial Hospital, Bangalore, Karnataka, India.
P6-08-13 Impact of Nueva Vida's model on quality of life, distress levels and self-efficacy in Latinas with breast cancer
Darling M, Caicedo L, BrintzenhofeSzoc K, Zabora J, Campos C, Blinka M, Gonzalez F. Nueva Vida, Washington, DC; The Catholic University of America, Washington, DC.
P6-08-14 Meeting needs and expectations of breast cancer survivors: Learning from patients through a survey method
Silverman P, Mazanec S, Gallagher P, Miano S, Lyons JA, Rowehl-Miano W, Daly B. University Hospitals Seidman Cancer Center, Cleveland, OH; Case Western Reserve School of Nursing, Cleveland, OH.
P6-08-15 Implementation of electronic client-level data collection via tablet technology among organizations supported by the Avon breast health outreach program
Hallum-Montes RM, Opdyke KM, Ruggeri C, Aliaga M, Bal D, Hurlbert M, Gates-Ferris K. CAI Global, New York, NY; Avon Foundation for Women, New York, NY.
  Treatment: Adjuvant Therapy - Other
P6-09-01 Central Ki67 analysis as a predictor for adjuvant capecitabine efficacy in early breast cancer (EBC) subtypes in US oncology trial 01062
O'Shaughnessy J, Koeppen H, Crockett M, Lackner M, Spoerke JM, Wilson T, Levin MK, Pippen J, Paul D, Stokoe C, Blum J, Holmes FA, Lindquist DL, Krekow L, Vukelja SJ, Sedlacek S, Rivera R, Brooks RJ, McIntyre KJ, Schwartz JE, Jones S. US Oncology, McKesson Specialty Health, The Woodlands, TX; Texas Oncology-Baylor Sammons Cancer Center', Dallas, TX; Genetech, South San Francisco, CA; Texas Oncology - Plano East, Plano, TX; Texas Oncology - Houston Memorial City, Houston, TX; Arizona Oncology Associates, Sedona, AZ; Texas Oncology - The Breast Care Center of North Texas, Bedford, TX; Texas Oncology - Tyler, Tyler, TX; Rocky Mountain Cancer Centers, Denver, CO; Texas Oncology - El Paso West, El Paso, TX; Arizona Oncology Associates, Tucson, AZ; Texas Oncology - Dallas Presbyterian Hospital, Dallas, TX.
P6-09-02 Improved clinical outcomes associated with vitamin D supplementation during adjuvant chemotherapy in patients with HER2+ non-metastatic breast cancer
Zeichner SB, Shah NN, Montero AJ, Markward NJ, Gluck S, Silva O, Ahn ER. Mount Sinai Medical Center, Miami Beach, FL; University of Miami Miller School of Medicine, Miami, FL; University of Miami/Sylvester Comprehensive Cancer Center, Miami, FL; United HealthCare, New Orleans, LA.
P6-09-03 Improved clinical outcomes associated with statin use during adjuvant chemotherapy in patients with HER2+ non-metastatic breast cancer
Zeichner SB, Shah NN, Montero AJ, Gluck S, Ahn E. Mount Sinai Medical Center, Miami Beach, FL; University of Miami Miller School of Medicine, Miami, FL; University of Miami/Sylvester Comprehensive Cancer Center, Miami, FL.
P6-09-04 M2 macrophages induced by mammary carcinoma are switched to M1 macrophages by Escherichia coli maltose-binding protein
Wang W, Guo Y, Xing H, Tai G. Institution of Jilin Province, China-Japan Union Hospital, Jilin University, Changchun, Jilin, China; China-Japan Union Hospital, Jilin University, Changchun, Jilin, China; Norman Bethune College of Medicine, Changchun, Jilin, China.
P6-09-05 Neem leaf extract, rich in nimbolide and azadirachtin targets radiation-induced stemness in surviving breast cancer cells
Pandian V, Natarajan M, Aravindan S, Herman TS, Aravindan N. University of Oklahoma Health Sciences Center, Oklahoma City, OK; University of Texas Health Sciences Center at San Antonio, San Antonio, TX; Stephensons Cancer Center, Oklahoma City, OK.
P6-09-06 Estrogen (E2) suppression following diagnosis of node positive (N+) breast cancer (BC) in premenopause. Long term follow-up of a phase II study
Recchia F, Candeloro G, Cesta A, Evangelista ML, Desideri G, Necozione S, Rea S. Civilian Hospital, Avezzano, AQ, Italy; Department of Internal Medicine and Public Health, L'Aquila, AQ, Italy; Department of Experimental Medicine, L'Aquila, AQ, Italy.
P6-09-07 Heterogeneity of the adjuvant chemotherapy decisions and guidelines use in early breast cancer: Results of a French national survey
Fekih M, Petit T, Zarca D, Guinebretière J-M, André F, Pierga J-Y, Namer M, Gligorov J, Delaloge S. Breast Cancer Group, Institut de Cancérologie Gustave Roussy, Villejuif, France; Centre Paul Strauss, Strasbourg, France; Institut Hartmann, Neuilly sur Seine, France; Institut Curie, Saint Cloud, France; Institut Curie, Paris, France; Cours National Saint Paul de Vence, Mougins, France; Hôpital Tenon, Paris, France.
P6-09-08 Withania somnifera extract inhibits invasion and metastasis of MDA-MB-231 cells by inhibiting CCL2 and CD44 high/CD24low stem cells
Khazal KF, Simon L, Odemuyiwa S, Hill D, Grubbs C. Tuskegee University, Tuskegee, AL.
P6-09-09 A second-generation proteasome inhibitor (SGPI) inhibits proliferation of triple negative breast cancer cells to a greater extent than doxorubicin while decreasing IL-6/NF-kB pathway inflammatory activity
Vyas D, Lopez N, Chaturvedi L, Vyas A. Michigan State University.
P6-09-10 Impact of a tailored oral vitamin D supplementation regimen on serum 25-hydroxy vitamin D levels in early breast cancer patients: A randomized phase III study
Jacot W, Firmin N, Roca L, Topart D, Gallet S, Durigova A, Mirr S, Pouderoux S, Bleuse J-P, Lamy P-J, Romieu G. ICM - Montpellier Cancer Center, Montpellier, France; Montpellier University Hospital, Montpellier, France.
  Treatment: Advanced Therapy - Other
P6-10-01 Evaluation of post-progression survival (PPS) in advanced breast cancer (ABC) according to treatment line: Correlation with PFS and OS in an unselected population
Ciccarese M, Forcignanò R, Petrucelli L, Fabi A, Chiuri VE, Cairo G, Lupo L, Gambino A, Saracino V, Ronzino G, Licchetta A, Giannarelli D. "Vito Fazzi" Hospital, Lecce, Italy; Regina Elena Cancer Institute, Rome, Italy.
P6-10-02 Breast cancer associated trials: Updates from the ClinicalTrials.gov database
Dawood S, Dent R, Sirohi B, Cortes J. Dubai Hospital, Dubai, UAE; National Cancer Center, Singapore; Tata Memorial Hospital, India; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
P6-10-03 Comparative efficacy of everolimus in combination with exemestane and chemotherapy for advanced breast cancer in terms of progression-free survival
Cope S, Zhang J, Smiechowski B, Gurunath S, Saletan S, Jansen JP, Schmid P. Mapi, Toronto, ON, Canada; Novartis Pharmaceuticals Corporation, Florham Park, NJ; Mapi, Boston, MA; Brighton and Sussex Medical School, University of Sussex, Brighton, United Kingdom.
P6-10-04 Stat5a/Jack2 overexpression sensitizes therapy resistant CD44+/CD24-breast cancer stem cell subpopulations to docetaxel and/or cannabidiol treatment through mediating differentiation
Sultan AS, Sherif ZA. Alexandria University, Alexandria, Egypt; Howard University College of Medicine, Washington, DC.
P6-10-05 First-line chemotherapy versus first-line endocrine therapy in hormone receptor positive HER2 negative patients with metastatic breast cancer in China: Results of the study of breast cancer group of the Chinese Society of Clinical Oncology (CSCO)
Wang T, Yang TT, Yang LJ, Song HY, Ouyang CQ, Wang JX, Hu CX, Zhang JG, Xu HB, Feng FJ, Tong SZ, Jiang FZ. Hospital Affiliated AMMS, Beijing, China; PLA 301 Hospital, Beijing, China; Hunan Cancer Hospital, Changsha, Hunan, China; Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China; Fudan University Shanghai Cancer Center, Shanghai, China; Cancer Center Affiliated Shantou University Medical College, Guangdong, China; Cancer Institute and Hospital Affiliated CAMS, Beijing, China; Jiangsu Cancer Hospital, Jiangsu, China; Tianjin Cancer Hospital, Tianjin, China.
  Treatment: Brain Metastases
P6-11-01 A randomized phase II clinical trial of whole-brain radiation therapy plus concomitant temozolomide in treatment of brain metastases from breast cancer: Six-month follow-up results
Cao KI, Lebas N, Gerber S, Levy C, Le Scodan R, Marsiglia H, Bourgier C, Pierga J-Y, Gobillion A, Savignoni A, Kirova YM. Institut Curie - Site Saint Cloud, Saint Cloud, France, Metropolitan; Institut Curie - Site Paris, Paris, France, Metropolitan; Centre François Baclesse, Caen, France, Metropolitan; Institut Gustave Roussy, Villejuif, France, Metropolitan.
P6-11-02 Patient characteristics and outcomes for patients with HER2-overexpressing breast cancer with brain metastases undergoing radiation therapy in the pre- and post adjuvant trastuzumab era
Morikawa A, Diab A, Patil S, Yang TJ, Hudis CA, McArthur HL, Beal K, Seidman AD. Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, NY; Memorial Sloan-Kettering Cancer Center, New York, NY.
P6-11-03 Follow up of breast cancer patients who underwent gamma knife radiosurgery for a diagnosis of brain metastases: A single institutional experience
Abu-Khalaf MM, Hatzis C, Chung G, DiGiovanna M, Tara S, Erin H, Lajos P, James YB, Veronica CL. Yale University School of Medicine; Yale Cancer Center, New Haven, CT; Yale University School of Medicine;Yale Cancer Center, New Haven, CT.
P6-11-04 Profound prevention of experimental brain metastases of breast cancer by temozolomide in a MGMT-dependent manner
Jassem J, Duchnowska R, Hua E, Qian Y, Biernat W, Sosinska-Mielcarek K, Gril B, Stark A, Hewitt S, Liewehr DJ, Steinberg SM, Palmieri D, Steeg PS. Medical University of Gdansk, Gdansk, Poland; Women's Cancers Section, Laboratory of Molecular Pharmacology, Center for Cancer Research, NCI, NIH, Bethesda, MD; National Heart, Lung and Blood Institute, NIH, Bethesda, MD; Military Institute of Medicine, Warsaw, Poland; Regional Cancer Center, Gdansk, Poland; Laboratory Animal Sciences Program, SAIC-Frederick, NCI, NIH, Frederick; Klinik fur Neurochirurgie UKSH Campus Kiel, Kiel, Germany; Laboratory of Pathology, Center for Cancer Research, NCI, NIH, Bethesda, MD; NCI, NIH, Bethesda, MD.
P6-11-05 ANG4043, a brain-penetrant anti-HER2 mAb increases survival in mice bearing intracranial BT-474 breast tumor cells
Lachowicz JE, Demeule M, Regina A, Houle E, Tripathy S, Castaigne J-P. Angiochem, Montreal, QC, Canada.
P6-11-06 Efficacy of carboplatin alone or with ABT888 in an intracranial murine model of BRCA-mutated, basal-like, triple negative breast cancer (TNBC)
Karginova O, Adamo B, Deal A, Santos C, Darr D, Bash R, Sandison K, Zamboni B, Miller CR, Anders CK. University of North Carolina, Chapel Hill, NC; Vall d'Hebron Institute of Oncology, Barcelona, Spain.
P6-11-07 Quantitative p95HER2 levels in primary breast cancers and in matched brain metastases
Duchnowska R, Sperinde J, Chenna A, Huang W, Weidler J, Winslow J, Haddad M, Paquet A, Lie Y, Trojanowski T, Mandat T, Kowalczyk A, Czartoryska-Arlukowicz B, Radecka B, Jarosz B, Staszkiewicz R, Kalinka-Warzocha E, Chudzik M, Biernat W, Jassem J. Military Institute of Medicine, Warsaw, Poland; Monogram Biosciences, Integrated Oncology, LabCorp, South San Francisco, CA; Medical University of Lublin, Lublin, Poland; Institute of Oncology, Warsaw, Poland; Medical University of Gdansk, Gdansk, Poland; Bialystok Oncology Center, Bialystok, Poland; Opole Oncology Center, Opole, Poland; Interior Affairs Hospital, Olsztyn, Poland; Regional Oncology Center, Lodz, Poland; Oncology Center, Warsaw, Poland.
P6-11-08 Risk of CNS relapse following adjuvant trastuzumab therapy – Updated literature-based meta-analysis
Mathew A, Brufsky AM. University of Pittsburgh Cancer Institute, Pittsburgh, PA.
P6-11-09 Impact of tumor subtype on clinical features, treatment, and clinical outcomes among breast cancer patients with central nervous system disease
Meier CA, Vaz-Luis I, Seah D, Macrae EM, Burstein HJ, Sohl J, Arvold ND, Winer EP, Lin NU. Dana-Farber Cancer Institute; Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
P6-11-10 Central nervous system metastases in breast cancer: Impact of tumour sub-type and outcome from current treatments
Chan A, O'Carrigan B, McGregor S, Beith J. Breast Cancer Research Centre-WA and Curtin University, Perth, Western Australia, Australia; Royal Prince Alfred Hospital, Sydney, NSW, Australia.
P6-11-11 Characteristics of long-term survivors after brain metastases in breast cancer patients
Honda Y, Aruga T, Goto R, Idera N, Horiguchi K, Kitagawa D, Miyamoto H, Yamashita T, Kuroi K. Cancer and Infectious Disease Center Tokyo Metropolitan Komagome Hospital, ToKyo, Japan.
P6-11-12 CNS metastases in breast cancer: A comparison report
Bourdeanu L, Reilly AA, Luu T. The Sage Colleges, Troy, NY; University of Albany School of Public Health and Wadsworth Center, NYS Department of Health, Albany, NY; City of Hope National Medical Center, Duarte, CA.
  Treatment: Inflammatory Breast Cancer
P6-12-01 Survival of women with inflammatory breast cancer: A large population based study
Dawood S, Lei X, Dent R, Gupta S, Sirohi B, Cortes J, Cristofanilli M, Bucholz T, Gonzalez-Angulo AM. Dubai Hospital; MD Anderson Cancer Center; National Cancer Center Singapore; Tata Memorial Center; Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology; Jefferson Kimmel Cancer Center.
P6-12-02 Survival differences between patients with metastatic inflammatory and non-inflammatory breast cancer
Fouad TM, Kogawa T, Liu DD, Shen Y, Masuda H, El-Zein R, Woodward WA, Arun B, Chavez-Macgregor M, Alvarez RH, Lucci A, Krishnamurthy S, Hortobagyi GN, Valero V, Ueno NT. The University of Texas MD Anderson Cancer Center, Houston, TX; The National Cancer Institute, Cairo University, Cairo, Egypt.
P6-12-03 Predictors of poor clinical outcome among patients with inflammatory breast cancer (IBC) who did and did not achieve pathological complete response (pCR) after neoadjuvant systemic chemotherapy
Masuda H, Chavez-Mac Gregor M, Liu DD, Alvarez RH, Krishnamurthy S, Lucci A, Woodward W, Gildy B, Mittendorf EA, DeSnyder SM, Shen Y, Willey JS, Hortobagyi GN, Valero V, Ueno NT. The University of Texas MD Anderson Cancer Center, Houston, TX.
P6-12-04 Risk factors for inflammatory breast cancer
Atkinson RL, El-Zein RA, Fouad TM, Alvarez de Lacerda LC, Wolfe AR, Bondy ML, Ueno NT, Woodward WA, Brewster AM. University of Texas MD Anderson Cancer Center, Houston, TX; Baylor College of Medicine, Houston, TX.
P6-12-05 The impact of residual disease after preoperative systemic therapy on clinical outcomes in patients with inflammatory breast cancer
Nakhlis F, Regan MM, Warren LE, Bellon JR, Yeh ED, Jacene HA, Golshan M, Duggan MM, Dominici LS, Hirshfield-Bartek J, Mullaney EE, Overmoyer BA. Dana Farber/Brigham and Women's Cancer Center, Boston, MA.
P6-12-06 Three-year follow up results of a phase II study of neoadjuvant bevacizumab, chemotherapy, and trastuzumab in HER2-positive inflammatory breast cancer: BEVERLY2 study
Viens P, Petit T, Lévy C, Ferrero J-M, Campone M, Gligorov J, Lerebours F, Roché H, Bachelot T, Charafe-Jauffret E, Bidard F-C, Bonneterre J, Coudert M, Hernandez J, Pierga J-Y. Insitut Paoli-Calmettes, Marseille, France; Centre Paul Strauss, Strasbourg, France; Centre de Lutte Contre le Cancer François Baclesse, Caen, France; Centre Antoine Lacassagne, Nice, France; Institut de Cancérologie de l'Ouest, Saint Herblain, France; APHP Tenon, APREC, University Cancer Institute-ParisVI Sorbonne University, Paris, France; Institut Curie-Hôpital René Huguenin, St Cloud, France; Institut Claudius Regaud, Toulouse, France; Centre Léon Bérard, Lyon, France; Institut Curie, Paris, France; Centre Oscar Lambret, Lille, France; Techno 5, Nanterre, France; Roche SAS, Boulogne-Billancourt, France.
P6-12-07 Prevalence of propionibacterium acnes and bartonella henselae DNA in patients with inflammatory breast cancer (IBC)
Fernandez SV, Alpaugh RK, Aburto L, He J, Nahas M, Otto G, Stephens P, Palmer G, Cristofanilli M, Lipson D. Thomas Jefferson University, Philadelphia, PA; Fox Chase Cancer Center, Philadelphia, PA; Foundation Medicine, Cambridge, MA.
P6-12-08 Serum biomarkers identification using quantitative proteomics in patients with HER2-positive inflammatory breast cancer receiving trastuzumab plus bevacizumab-based chemotherapy (BEVERLY 2 trial)
Gonçalves A, Camoin L, Pierga J-Y, Petit T, Delozier T, Ferrero J-M, Campone M, Gligorov J, Lerebours F, Roché H, Bachelot T, Charafe-Jauffret E, Ben Younes I, Borg J-P, Viens P. Institut Paoli-Calmettes, Marseille, France; Institut Curie, Paris, France; Centre Paul-Strauss, Strasbourg, France; Centre François-Baclesse, Caen, France; Centre Antoine-Lacassagne, Nice, France; Institut de Cancérologie de l'Ouest-René Gauducheau, Siant-Herbin, France; Hôpital Tenon, Paris, France; Centre René-Huguenin, Paris, France; Institut Claudius-Regaud, Toulouse, France; Centre Léon-Berard, Lyon, France
P6-12-09 Targeting deregulated cyclin E in inflammatory breast cancer via sequential combination therapy
Alexander A, Karakas C, Gong Y, Alvarez R, Ueno NT, Keyomarsi K. University of Texas MD Anderson Cancer Center, Houston, TX.
P6-12-10 Withdrawn
P6-12-11 Celecoxib inhibits the growth of IBC tumors by suppressing the regulation of cancer stem-like cells by nodal
Reyes ME, Zhang D, Eckhardt B, Masuda H, Pirman DA, Reuben JM, Woodward W, Yang P, Hortobagyi GN, Wang X, Ueno NT. M.D. Anderson Cancer Center, Houston, TX.
P6-12-12 MiR-19a released by the triple negative inflammatory breast cancer SUM149 cells can be taken up by dendritic cells and induce increased synthesis of the proinflammatory cytokines IL-6 and TNF-a
Anfossi S, Burks JK, Giordano A, Cohen EN, Gao H, Debeb BG, Woodward W, Ueno NT, Ricardo AH, Hortobagyi GN, Valero V, Reuben JM. University of Texas MD Anderson Cancer Center, Houston, TX.
P6-12-13 Synchronous metastases are highly prevalent in HER2 positive inflammatory breast carcinomas evaluated by 18F-FDG PET/CT
Wassermann J, Groheux D, Coussy F, Cuvier C, Huon De Kermadec E, Banayan S, Albiter M, De Bazelaire C, Lalloum M, De Roquancourt A, Bourstyn E, Cahen-Doidy L, Hindié E, Espié M, Giacchetti S. Saint-Louis University Hospital, Paris, France.
P6-12-14 Histone deacetylase inhibitor suberoylanilide hydroxamic acid targets breast cancer stem cells and inhibits metastasis
Chu K, Green TL, Boley KM, Cristofanilli M, Robertson FM. The University of Texas M.D. Anderson Cancer Center, Houston, TX; Thomas Jefferson University, Philadelphia, PA.
P6-12-15 Preclinical testing of a novel platelet derived growth factor receptor alpha (PDGFRα) inhibitor in inflammatory breast cancer
Joglekar M, Van Laere S, Vermeulen P, Dirix L, Carter M, Rhamchandran A, van Golen KL. University of Delaware, Newark, DE; Translational Cancer Research Unit, Antwerp, Belgium; AROG Pharmaceuticals, Dallas, TX.
P6-12-16 Treatment with indol-3-carbinol (I3C) in a mice xenograft model of canine breast carcinoma alter hormone metabolism and produce liver metastases
Illera JC, Martin-Ruz AL, Caceres S, Diez L, Gonzalez-Gil A, Peña L. University Complutense de Madrid, Madrid, Spain.
Home | About SABCS | Press Releases | Media | Event Photos | Past Symposia | Satellite Symposia | Patient Advocates | FAQs | Contact Us
Registration | Hotel | Support & Exhibits | 2014 Overview | Program | Travel & Transportation

Rich Markow, Director, Symposia
Cancer Therapy & Research Center at UT Health Science Center San Antonio

7979 Wurzbach Road, MC 8224 San Antonio, TX 78229 USA
Phone: 210-450-1550    Fax: 210-450-1560    Email: sabcs@uthscsa.edu
Copyright © 2014 SABCS. All rights reserved. - Privacy Policy